Amicus Therapeutics is a global biopharmaceutical brand specializing in the development of innovative therapies for rare and devastating diseases. With headquarters in Philadelphia, PA, and offices across the globe, they are dedicated to improving the lives of patients worldwide. At Amicus Therapeutics, their mission is to provide hope and relief to those affected by rare diseases.

They offer a range of products and services designed to address unmet medical needs and bring about meaningful change. Their pipeline of therapies includes treatments for Fabry Disease, Pompe Disease, Batten Disease, and additional preclinical programs. By prioritizing patient advocacy, Amicus Therapeutics ensures that their programs and resources are focused on delivering the best possible care and support.

They actively engage with patient advisory boards and share rare stories to foster a sense of community and empower patients. Through their commitment to responsibility, ethics, and compliance, Amicus Therapeutics demonstrates their dedication to making a positive impact beyond disease. They prioritize global medical affairs, corporate giving, and environmental, social, and governance initiatives.

For more information or to get in touch with Amicus Therapeutics, visit their website or contact their global offices. They are ready to collaborate with healthcare professionals, investors, media, and individuals interested in careers with a purpose